Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study
- Design
- Retrospective cohort · Unknown outcome
- Match to healthy normal-weight adults aged 55–75
- Population unclear[Auto] Population characteristics not extractable from abstract (age/BMI not reported in abstract). Needs manual review.
- Could weight loss explain it?
- Unknown[Auto] Not addressed in abstract.
- Study tier
- Preliminary[Auto] Not peer reviewed (preprint, abstract or registration). Early-warning only.
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 20, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75. This item has not been peer reviewed.
[Auto, unreviewed; last sentences of abstract] Results of the second cohort demonstrated 38% lower odds of any side effect by week 16 among NMGP users (n=958 per group, p=0.019). ConclusionsLower doses of compounded semaglutide alongside a behavioral companion are associated with fewer side effects in the first 16 weeks compared to a higher dose program.
01Findings
What the study reported
- Drugs
- Semaglutide
- Dose
- 0.6mg/week
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- 16 weeks
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
Study quality details
- Study design
- Retrospective cohort
- Sample size
- not extracted
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- 16 weeks
- Outcome type
- unknown
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- UNKNOWN
- Statistical precision
- not extracted
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- no
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- not available in metadata
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
ObjectiveEvaluate differences in side effects between a low and standard dose compounded semaglutide paired with a behavioral companion in the first 16 weeks of treatment using a real-world, retrospective cohort. MethodsSide effects were compared between the low dose protocol (Noom Microdose GLP-1 Rx Program; NMGP, up to 0.6mg/weekly compounded semaglutide) and Nooms standard dose of compounded semaglutide (Noom GLP-1 Rx Program; NGP, up to 1.2mg/weekly). Users were propensity score matched on side effect rate in the first 8 weeks when dosing protocols were identical, and longitudinal side effect trajectories were compared via logistic regression. Analyses were conducted on a second cohort with additional matched baseline characteristics. ResultsThe full sample included 7,682 NGP and 2,877 NMGP users. NMGP users had 34% lower and 29% lower relative odds of reporting GI side effects (p=0.001) and any side effects (p=0.001) by week 16, respectively (n=2,481 per group). Results of the second cohort demonstrated 38% lower odds of any side effect by week 16 among NMGP users (n=958 per group, p=0.019). ConclusionsLower doses of compounded semaglutide alongside a behavioral companion are associated with fewer side effects in the first 16 weeks compared to a higher dose program.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| medrxiv:medrxiv | Sep 20, 2026 | 10.64898/2026.09.08.26362532 first ingestion |